Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer was previously referred to as metastatic hormone-sensitive prostate cancer.

AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...

AstraZeneca’s Truqap (capivasertib) gained FDA approval, combined with abiraterone and prednisone, for treatment of certain ...

AstraZeneca PLC AZN announced that the FDA has approved an expanded use of its breast cancer drug, Truqap (capivasertib), for ...

AstraZeneca has received US FDA approval for TRUQAP (capivasertib) as the first targeted treatment for PTEN-deficient ...

The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway ...

“Prostate cancer is one of the leading cancer diagnoses for men in the United States,” said Matt Sause, CEO of Roche Diagnostics. “The FDA approval of our new companion diagnostic will provide ...